Eintrag weiter verarbeiten
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
Gespeichert in:
| Zeitschriftentitel: | BMC Cancer |
|---|---|
| Personen und Körperschaften: | , , , , , , , |
| In: | BMC Cancer, 10, 2010, 1 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Springer Science and Business Media LLC
|
| Schlagwörter: |
| author_facet |
Gjerde, Jennifer Geisler, Jürgen Lundgren, Steinar Ekse, Dagfinn Varhaug, Jan Erik Mellgren, Gunnar Steen, Vidar M Lien, Ernst A Gjerde, Jennifer Geisler, Jürgen Lundgren, Steinar Ekse, Dagfinn Varhaug, Jan Erik Mellgren, Gunnar Steen, Vidar M Lien, Ernst A |
|---|---|
| author |
Gjerde, Jennifer Geisler, Jürgen Lundgren, Steinar Ekse, Dagfinn Varhaug, Jan Erik Mellgren, Gunnar Steen, Vidar M Lien, Ernst A |
| spellingShingle |
Gjerde, Jennifer Geisler, Jürgen Lundgren, Steinar Ekse, Dagfinn Varhaug, Jan Erik Mellgren, Gunnar Steen, Vidar M Lien, Ernst A BMC Cancer Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer Cancer Research Genetics Oncology |
| author_sort |
gjerde, jennifer |
| spelling |
Gjerde, Jennifer Geisler, Jürgen Lundgren, Steinar Ekse, Dagfinn Varhaug, Jan Erik Mellgren, Gunnar Steen, Vidar M Lien, Ernst A 1471-2407 Springer Science and Business Media LLC Cancer Research Genetics Oncology http://dx.doi.org/10.1186/1471-2407-10-313 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-<jats:italic>N</jats:italic>-demethyltamoxifen (4OHNDtam, endoxifen). Inter-individual variations of the activity of these enzymes due to polymorphisms may be predictors of outcome of breast cancer patients during tamoxifen treatment. Since tamoxifen and estrogens are both partly metabolized by these enzymes we hypothesize that a correlation between serum tamoxifen and estrogen levels exists, which in turn may interact with tamoxifen on treatment outcome. Here we examined relationships between the serum levels of tamoxifen, estrogens, follicle-stimulating hormone (FSH), and also determined the genotypes of CYP2C19, 2D6, 3A5, and SULT1A1 in 90 postmenopausal breast cancer patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Tamoxifen and its metabolites were measured by liquid chromatography-tandem mass spectrometry. Estrogen and FSH levels were determined using a sensitive radio- and chemiluminescent immunoassay, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We observed significant correlations between the serum concentrations of tamoxifen, <jats:italic>N</jats:italic>-dedimethyltamoxifen, and tamoxifen-<jats:italic>N</jats:italic>-oxide and estrogens (p < 0.05). The genotype predicted CYP2C19 activity influenced the levels of both tamoxifen metabolites and E1.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.</jats:p> </jats:sec> Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer BMC Cancer |
| doi_str_mv |
10.1186/1471-2407-10-313 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Biologie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Ni8xNDcxLTI0MDctMTAtMzEz |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Ni8xNDcxLTI0MDctMTAtMzEz |
| institution |
DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 |
| imprint |
Springer Science and Business Media LLC, 2010 |
| imprint_str_mv |
Springer Science and Business Media LLC, 2010 |
| issn |
1471-2407 |
| issn_str_mv |
1471-2407 |
| language |
English |
| mega_collection |
Springer Science and Business Media LLC (CrossRef) |
| match_str |
gjerde2010associationsbetweentamoxifenestrogensandfshserumlevelsduringsteadystatetamoxifentreatmentofpostmenopausalwomenwithbreastcancer |
| publishDateSort |
2010 |
| publisher |
Springer Science and Business Media LLC |
| recordtype |
ai |
| record_format |
ai |
| series |
BMC Cancer |
| source_id |
49 |
| title |
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_unstemmed |
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_full |
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_fullStr |
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_full_unstemmed |
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_short |
Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_sort |
associations between tamoxifen, estrogens, and fsh serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| topic |
Cancer Research Genetics Oncology |
| url |
http://dx.doi.org/10.1186/1471-2407-10-313 |
| publishDate |
2010 |
| physical |
|
| description |
<jats:title>Abstract</jats:title>
<jats:sec>
<jats:title>Background</jats:title>
<jats:p>The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-<jats:italic>N</jats:italic>-demethyltamoxifen (4OHNDtam, endoxifen). Inter-individual variations of the activity of these enzymes due to polymorphisms may be predictors of outcome of breast cancer patients during tamoxifen treatment. Since tamoxifen and estrogens are both partly metabolized by these enzymes we hypothesize that a correlation between serum tamoxifen and estrogen levels exists, which in turn may interact with tamoxifen on treatment outcome. Here we examined relationships between the serum levels of tamoxifen, estrogens, follicle-stimulating hormone (FSH), and also determined the genotypes of CYP2C19, 2D6, 3A5, and SULT1A1 in 90 postmenopausal breast cancer patients.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Methods</jats:title>
<jats:p>Tamoxifen and its metabolites were measured by liquid chromatography-tandem mass spectrometry. Estrogen and FSH levels were determined using a sensitive radio- and chemiluminescent immunoassay, respectively.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Results</jats:title>
<jats:p>We observed significant correlations between the serum concentrations of tamoxifen, <jats:italic>N</jats:italic>-dedimethyltamoxifen, and tamoxifen-<jats:italic>N</jats:italic>-oxide and estrogens (p < 0.05). The genotype predicted CYP2C19 activity influenced the levels of both tamoxifen metabolites and E1.</jats:p>
</jats:sec>
<jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.</jats:p>
</jats:sec> |
| container_issue |
1 |
| container_start_page |
0 |
| container_title |
BMC Cancer |
| container_volume |
10 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792335941115838467 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:52:33.098Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Associations+between+tamoxifen%2C+estrogens%2C+and+FSH+serum+levels+during+steady+state+tamoxifen+treatment+of+postmenopausal+women+with+breast+cancer&rft.date=2010-12-01&genre=article&issn=1471-2407&volume=10&issue=1&jtitle=BMC+Cancer&atitle=Associations+between+tamoxifen%2C+estrogens%2C+and+FSH+serum+levels+during+steady+state+tamoxifen+treatment+of+postmenopausal+women+with+breast+cancer&aulast=Lien&aufirst=Ernst+A&rft_id=info%3Adoi%2F10.1186%2F1471-2407-10-313&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792335941115838467 |
| author | Gjerde, Jennifer, Geisler, Jürgen, Lundgren, Steinar, Ekse, Dagfinn, Varhaug, Jan Erik, Mellgren, Gunnar, Steen, Vidar M, Lien, Ernst A |
| author_facet | Gjerde, Jennifer, Geisler, Jürgen, Lundgren, Steinar, Ekse, Dagfinn, Varhaug, Jan Erik, Mellgren, Gunnar, Steen, Vidar M, Lien, Ernst A, Gjerde, Jennifer, Geisler, Jürgen, Lundgren, Steinar, Ekse, Dagfinn, Varhaug, Jan Erik, Mellgren, Gunnar, Steen, Vidar M, Lien, Ernst A |
| author_sort | gjerde, jennifer |
| container_issue | 1 |
| container_start_page | 0 |
| container_title | BMC Cancer |
| container_volume | 10 |
| description | <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-<jats:italic>N</jats:italic>-demethyltamoxifen (4OHNDtam, endoxifen). Inter-individual variations of the activity of these enzymes due to polymorphisms may be predictors of outcome of breast cancer patients during tamoxifen treatment. Since tamoxifen and estrogens are both partly metabolized by these enzymes we hypothesize that a correlation between serum tamoxifen and estrogen levels exists, which in turn may interact with tamoxifen on treatment outcome. Here we examined relationships between the serum levels of tamoxifen, estrogens, follicle-stimulating hormone (FSH), and also determined the genotypes of CYP2C19, 2D6, 3A5, and SULT1A1 in 90 postmenopausal breast cancer patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Tamoxifen and its metabolites were measured by liquid chromatography-tandem mass spectrometry. Estrogen and FSH levels were determined using a sensitive radio- and chemiluminescent immunoassay, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We observed significant correlations between the serum concentrations of tamoxifen, <jats:italic>N</jats:italic>-dedimethyltamoxifen, and tamoxifen-<jats:italic>N</jats:italic>-oxide and estrogens (p < 0.05). The genotype predicted CYP2C19 activity influenced the levels of both tamoxifen metabolites and E1.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.</jats:p> </jats:sec> |
| doi_str_mv | 10.1186/1471-2407-10-313 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Biologie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE4Ni8xNDcxLTI0MDctMTAtMzEz |
| imprint | Springer Science and Business Media LLC, 2010 |
| imprint_str_mv | Springer Science and Business Media LLC, 2010 |
| institution | DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275 |
| issn | 1471-2407 |
| issn_str_mv | 1471-2407 |
| language | English |
| last_indexed | 2024-03-01T14:52:33.098Z |
| match_str | gjerde2010associationsbetweentamoxifenestrogensandfshserumlevelsduringsteadystatetamoxifentreatmentofpostmenopausalwomenwithbreastcancer |
| mega_collection | Springer Science and Business Media LLC (CrossRef) |
| physical | |
| publishDate | 2010 |
| publishDateSort | 2010 |
| publisher | Springer Science and Business Media LLC |
| record_format | ai |
| recordtype | ai |
| series | BMC Cancer |
| source_id | 49 |
| spelling | Gjerde, Jennifer Geisler, Jürgen Lundgren, Steinar Ekse, Dagfinn Varhaug, Jan Erik Mellgren, Gunnar Steen, Vidar M Lien, Ernst A 1471-2407 Springer Science and Business Media LLC Cancer Research Genetics Oncology http://dx.doi.org/10.1186/1471-2407-10-313 <jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>The cytochrome P450 (CYP) enzymes 2C19, 2D6, and 3A5 are responsible for converting the selective estrogen receptor modulator (SERM), tamoxifen to its active metabolites 4-hydroxy-tamoxifen (4OHtam) and 4-hydroxy-<jats:italic>N</jats:italic>-demethyltamoxifen (4OHNDtam, endoxifen). Inter-individual variations of the activity of these enzymes due to polymorphisms may be predictors of outcome of breast cancer patients during tamoxifen treatment. Since tamoxifen and estrogens are both partly metabolized by these enzymes we hypothesize that a correlation between serum tamoxifen and estrogen levels exists, which in turn may interact with tamoxifen on treatment outcome. Here we examined relationships between the serum levels of tamoxifen, estrogens, follicle-stimulating hormone (FSH), and also determined the genotypes of CYP2C19, 2D6, 3A5, and SULT1A1 in 90 postmenopausal breast cancer patients.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Tamoxifen and its metabolites were measured by liquid chromatography-tandem mass spectrometry. Estrogen and FSH levels were determined using a sensitive radio- and chemiluminescent immunoassay, respectively.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We observed significant correlations between the serum concentrations of tamoxifen, <jats:italic>N</jats:italic>-dedimethyltamoxifen, and tamoxifen-<jats:italic>N</jats:italic>-oxide and estrogens (p < 0.05). The genotype predicted CYP2C19 activity influenced the levels of both tamoxifen metabolites and E1.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>We have shown an association between tamoxifen and its metabolites and estrogen serum levels. An impact of CYP2C19 predicted activity on tamoxifen, as well as estrogen kinetics may partly explain the observed association between tamoxifen and its metabolites and estrogen serum levels. Since the role of estrogen levels during tamoxifen therapy is still a matter of debate further prospective studies to examine the effect of tamoxifen and estrogen kinetics on treatment outcome are warranted.</jats:p> </jats:sec> Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer BMC Cancer |
| spellingShingle | Gjerde, Jennifer, Geisler, Jürgen, Lundgren, Steinar, Ekse, Dagfinn, Varhaug, Jan Erik, Mellgren, Gunnar, Steen, Vidar M, Lien, Ernst A, BMC Cancer, Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer, Cancer Research, Genetics, Oncology |
| title | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_full | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_fullStr | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_full_unstemmed | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_short | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_sort | associations between tamoxifen, estrogens, and fsh serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| title_unstemmed | Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer |
| topic | Cancer Research, Genetics, Oncology |
| url | http://dx.doi.org/10.1186/1471-2407-10-313 |